E-resources
Peer reviewed
Open access
-
Cortot, Alexis B.; Audigier-Valette, Clarisse; Molinier, Olivier; Le Moulec, Sylvestre; Barlesi, Fabrice; Zalcman, Gérard; Dumont, Patrick; Pouessel, Damien; Poulet, Claire; Fontaine-Delaruelle, Clara; Hiret, Sandrine; Dixmier, Adrien; Renault, Patrick-Aldo; Becht, Catherine; Raffy, Olivier; Dayen, Charles; Mazieres, Julien; Pichon, Eric; Langlais, Alexandra; Morin, Franck; Moro-Sibilot, Denis; Besse, Benjamin
European journal of cancer, 20/May , Volume: 131Journal Article
Second-line chemotherapy regimens have demonstrated poor benefit after failure of platinum-based chemotherapy in advanced non-squamous non–small-cell lung cancer (nsNSCLC). In this multicentre, open-label phase III trial, patients with advanced nsNSCLC treated with one or two prior lines, including one platinum-based doublet, were centrally randomised to receive 90 mg/m2 of paclitaxel (D1, D8, D15) plus 10 mg/kg of bevacizumab (D1, D15) every 28 days or docetaxel (75 mg/m2) every 21 days; crossover was allowed after disease progression. Primary end-point was progression-free survival (PFS). ClinicalTrials.gov registration number: NCT01763671. One hundred sixty six patients were randomised (paclitaxel plus bevacizumab: 111, docetaxel: 55). The median PFS was longer in patients receiving paclitaxel plus bevacizumab than in patients receveing docetaxel 5·4 months versus 3·9 months, adjusted hazard ratio (HR) 0·61 (95% confidence interval CI: 0·44–0·86); p = 0·005. Objective response rates (ORRs) were 22·5% (95% CI: 14·8–30·3) and 5·5% (95% CI: 0·0–11·5) (p = 0·006), respectively. Median overall survivals were similar (adjusted HR 1·17; p = 0·50). Crossover occurred in 21 of 55 (38·2%) docetaxel-treated patients. Grade III-IV adverse events (AEs) were reported in 45·9% and 54·5% of patients treated with paclitaxel and bevacizumab or docetaxel, respectively (p = NS), including neutropenia (19·3% versus 45·4%), neuropathy (8·3% versus 0·0%) and hypertension (7·3% versus 0·0%). Three patients died due to treatment-related AEs (1·8% in each group). Weekly paclitaxel plus bevacizumab as second- or third-line improves PFS and ORR compared with docetaxel in patients with nsNSCLC, with an acceptable safety profile. These results place weekly paclitaxel plus bevacizumab as a valid option in this population. ClinicalTrials.gov Identifier: NCT01763671. •Prognosis of patients with advanced non–small-cell lung cancer (NSCLC) is poor.•Few options beyond platinum-based chemo and immunotherapy in non-squamous (ns) NSCLC.•Phase III trial of bevacizumab-paclitaxel (wPB) or docetaxel in 2nd/3rd line nsNSCLC.•wPB improved progression-free survival and objective response rate.•Safety profile was manageable and Quality of Life was preserved with wPB.
Author
![loading ... loading ...](themes/default/img/ajax-loading.gif)
Shelf entry
Permalink
- URL:
Impact factor
Access to the JCR database is permitted only to users from Slovenia. Your current IP address is not on the list of IP addresses with access permission, and authentication with the relevant AAI accout is required.
Year | Impact factor | Edition | Category | Classification | ||||
---|---|---|---|---|---|---|---|---|
JCR | SNIP | JCR | SNIP | JCR | SNIP | JCR | SNIP |
Select the library membership card:
If the library membership card is not in the list,
add a new one.
DRS, in which the journal is indexed
Database name | Field | Year |
---|
Links to authors' personal bibliographies | Links to information on researchers in the SICRIS system |
---|
Source: Personal bibliographies
and: SICRIS
The material is available in full text. If you wish to order the material anyway, click the Continue button.